O-1 Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study

A He,J Valle,C Lee,M Ikeda,P Potemski,C Morizane,J Cundom,D Tougeron,F Dayyani,N Rokutanda,J Xiong,G Cohen,D Oh

doi:10.1016/j.annonc.2022.04.442

O-1 Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study

A He, J Valle + Show 11 more

Open Access

https://doi.org/10.1016/j.annonc.2022.04.442

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Jun 1, 2022
Citations: 4

Affiliation: Georgetown University, The Christie NHS Foundation Trust, National Health Service, Yonsei University, National Cancer Center Hospital East, Medical University of Lodz, Instituto de Diagnóstico e Investigaciones Metabólicas, Centre Hospitalier Universitaire de Poitiers, University of California, Irvine, AstraZeneca (United States), Seoul National University

#Primary Tumour Location #Advanced Biliary Tract Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The double-blind, phase 3 TOPAZ-1 study (NCT03875235) evaluated the efficacy and safety of durvalumab plus gemcitabine and cisplatin (GemCis) as first-line treatment for patients with advanced biliary tract cancer (BTC; Oh D-Y et al. J Clin Oncol 2022;40[suppl 4]. Abs 378). Durvalumab plus GemCis significantly improved overall survival (OS) versus placebo plus GemCis and represents a potential new first-line treatment option. In BTC, primary tumour location (intrahepatic or extrahepatic cholangiocarcinoma [IHCC/EHCC], or gallbladder cancer [GBC]) may impact risk factors, prognoses, and response to treatment.

Full Text